Alkmaar

• Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended recruitment
  2024-517467-23-00 5 2024-11-29 steroid sensitive idiopathic nephrotic syndrome
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NV … Ended recruitment
  2024-516195-15-00 5 2024-09-10 Advanced NSCLC
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• DUTCH-WAIST Ended recruitment
  2022-501392-81-00 6 2024-07-25 Atrial fibrillation
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended recruitment
  2023-504553-12-01 6 2023-12-27 Influenza
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended recruitment
  2022-502664-21-00 6 2023-05-01 multiple sclerosis
• SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat … Ended recruitment
  2024-514965-20-00 4 2022-06-02 Breast cancer
• LEGACY Ended recruitment
  2023-504360-42-00 6 2022-05-13 Non-ST-segment elevation acute coronary syndrome
• Personalized dosing of ocrelizumab in MS Ended recruitment
  2024-513193-22-00 11 2022-03-16 Multiple Sclerosis
• Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients Ended recruitment
  2024-514919-10-00 6 2022-01-24 Locally advanced head and neck squamous cell carcinoma
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-conce … Ended recruitment
  2023-509458-77-00 4 2021-01-04 Esophageal adenocarcinoma, esophageal cancer
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal … Ended recruitment
  2024-513422-38-00 5 2020-09-28 Newly diagnosed multiple myeloma
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma (Intrim 1 study) Ended recruitment
  2023-509461-20-00 4 2020-01-22 pT3-4 cN0M0 Melanoma
• Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended recruitment
  2024-516205-23-00 4 2019-04-09 Breast cancer
• DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended recruitment
  2024-513867-19-00 5 2019-01-31 metastatic Castration-Resistant Prostate Cancer (mCRPC)

Showing 49–72 of 91 trials